Polypharmacy, drug-drug interactions and the pharmacology of ageing – Dr. Marta Boffito

Welcome To eHIVeIntroduction
Training modules, presentations, learning materialsStart using our learning tools
Help & FeedbackGet in touch with us
Return to HIVPAGo to the main HIVPA site

Welcome to your Polypharmacy, drug-drug interactions and the pharmacology of ageing – Dr. Marta Boffito

Which of the following statements is true?

a. Biktarvy is metabolised by cytochrome P450

b. Bictegravir is never a victim of drug-drug interactions

c. Bictegravir is metabolised by approximately 50% by cytochrome P450

d. Raltegravir and bictegravir are identical drugs

Which of the following statements is true?

Raltegravir is:-

a. A strong perpetrator of drug-drug interactions

b. A novel non nucleoside reverse transcriptase inhibitor

c. A victim of the interaction with rifampicin

d. Dosed at 400mg once daily

Which of the following statements is false>

a. Unboosted integrase inhibitors are characterised by a low potential for drug-drug interactions

b. Elvitegravir/cobicistat is a victim of the interaction with rifampicin

c. Biktarvy should not be co-administered with rifabutin

d. Raltegravir is mainly metabolised by UGT1A1 (UDP-glucuronosyltransferase)

Which of the following statements is true?

On the http://www.hiv-druginteractions.org website:-

a. The red symbol means 'no clinically significant drug interaction expected'

b. The amber (orange) symbol means 'potential interaction - may require close monitoring alteration of drug dosage or timing of administration'

c. There are no green symbols

d. The website does not exist

Time's up